To evaluate the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia (BPH).
This was a 12-week, single-arm, open-label, prospective, multicenter study. The study included men 50 years or older with nocturia (≥2 events/night) based on a voiding diary, an International Prostate Symptom Score (IPSS) ≥8, and a quality of life score ≥3.